Jennison Associates LLC Boosts Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Jennison Associates LLC lifted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 47.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,178,580 shares of the company’s stock after buying an additional 698,712 shares during the quarter. Jennison Associates LLC owned about 5.73% of Tarsus Pharmaceuticals worth $71,653,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Cowen AND Company LLC lifted its position in shares of Tarsus Pharmaceuticals by 3.5% during the second quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock worth $59,725,000 after acquiring an additional 74,855 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Tarsus Pharmaceuticals by 14.5% during the 1st quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock valued at $66,398,000 after purchasing an additional 231,131 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Tarsus Pharmaceuticals by 7.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock worth $37,536,000 after purchasing an additional 77,825 shares in the last quarter. Driehaus Capital Management LLC boosted its stake in Tarsus Pharmaceuticals by 126.1% in the 2nd quarter. Driehaus Capital Management LLC now owns 364,463 shares of the company’s stock worth $9,906,000 after purchasing an additional 203,300 shares during the period. Finally, Millennium Management LLC grew its holdings in Tarsus Pharmaceuticals by 1,259.3% during the 2nd quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock valued at $9,475,000 after buying an additional 322,942 shares in the last quarter. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ:TARS opened at $46.58 on Thursday. The firm has a fifty day moving average of $38.71 and a 200 day moving average of $32.77. Tarsus Pharmaceuticals, Inc. has a 52-week low of $15.60 and a 52-week high of $52.99. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

Wall Street Analysts Forecast Growth

Several research analysts have commented on TARS shares. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Finally, The Goldman Sachs Group upped their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $54.20.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.